Exchange: NASDAQ·Updated 01:26 PM EDT
GHRS logo

GHRSGH Research PLC

$28.29
$0.755
(2.74%)
Today
EarningsAug 6
Mkt Cap$1.89B
Vol84,581.00
News
all
press releases
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire NEW YORK and TORONTO, July 21, 2026 Issued on behalf of...
PR Newswire
News Placeholder
More News
News Placeholder
ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside
H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.
Stocktwits
News Placeholder
Futures Slide After Another Korea Rout, TSMA Results Revive AI Fears
Futures Slide After Another Korea Rout, TSMA Results Revive AI Fears Futures are lower, erasing much of yesterday's gain with both Nasdaq and Rusell lagging SPX, following a continued rollercoaster in Korea where stocks tumbled after the BOK hired rates for the first time in 3 years...
Zero Hedge
News Placeholder
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?
ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.
Zacks
News Placeholder
AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs
ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.
Zacks
News Placeholder
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026
ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.
Zacks
News Placeholder
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
Next-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity   New York, NY – June 30, 2026 – Market News Updates News Commentary – The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often […] The post Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity appeared first on Financial News Media.
Financial News Media
News Placeholder
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...
PR Newswire
News Placeholder
GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages
GH Research PLC (NASDAQ:GHRS - Get Free Report) has received an average recommendation of 'Moderate Buy' from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One...
MarketBeat
News Placeholder
GH Research (GHRS) Expected to Announce Earnings on Thursday
GH Research (NASDAQ:GHRS) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-gh-research-plc-stock...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.